



Published in final edited form as:

Pharm Regul Aff. 2014 July ; 3(2): . doi:10.4172/2167-7689.1000118.

## AMPK Activators as a Drug for Diabetes, Cancer and Cardiovascular Disease

Mark Goodman<sup>1</sup>, Zhenling Liu<sup>1,2</sup>, Ping Zhu<sup>2</sup>, and Ji Li<sup>1,\*</sup>


<sup>1</sup>Department of Pharmacology and Toxicology, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY 14214, USA

<sup>2</sup>Department of Cardiovascular Surgery, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China

### Abstract

The cellular mechanisms of AMP-Activated Protein Kinase (AMPK) activators in the treatment and prevention of diabetes, cancer, and cardiovascular disease

### Graphical Abstract



### Introduction

AMP-Activated Protein Kinase (AMPK) is a protein kinase modulating energy metabolism. It was first identified in 1973 for its regulative effect in acetyl-CoA carboxylase (ACC) and 3-hydroxy-3-methyl-glutaryl (HMG)-CoA reductase [1,2]. The name of AMPK was adopted in 1989 to indicate its positive regulation by AMP nucleotide [3]. Since the discovery of AMPK, intense interest has been drawn exponentially to this major fuel gauge as a modulator of the cellular response to energy dysfunction. Agonists of AMPK such as aspirin, metformin, adiponectin, MIF (macrophage migration inhibitory factor), Activated Protein C etc. have been used to investigate the signal pathway. Such a pathway may potentially explain the strong association between cellular energy supply and various diseases such as diabetes, cancer, and cardiovascular disease. This review aims to discuss the

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

\*Corresponding author: Ji Li, Department of Pharmacology and Toxicology, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, 615 BRB, 3435 Main Street, Buffalo, NY 14214, USA, Tel: 716-829-5711; Fax: 716-829-5710; jli23@buffalo.edu.

It is equally contributed by Mark Goodman and Zhenling Liu.

mechanisms of AMPK agonists in diabetes, cancer, and cardiovascular diseases, therefore to shed light on the pros and cons of currently available AMPK activators.

## Structure of AMPK

AMPK is a widely distributed and highly conserved heterotrimeric complex composed of a catalytic  $\alpha$  (63KDa) subunit and the non-catalytic  $\beta$  and  $\gamma$  subunits which are responsible for the regulation of the kinase activity, enzyme stability, and localization [4]. The N-terminal half of the  $\alpha$  catalytic subunit is highly conserved among species and contains a serine/threonine kinase domain followed by an Auto-Inhibitory Sequence (AIS), a C-terminus containing the subunit interacting domains required for binding to  $\beta$  subunit ( $\beta$ -SID), and a conserved leptomycin-sensitive Nuclear Export Sequence (NES) [5].

The  $\beta$  subunit consists of a domain identified as Glycogen-Binding Domain (GBD). While the function of the GBD is still not clear it may serve to co-localize AMPK with downstream targets such as glycogen synthase [6]. The second domain of  $\beta$  subunit is called ASC or SBS (Subunit Binding Sequence), which interacts with both  $\alpha$  and  $\gamma$  subunits [7].

The  $\gamma$  subunit includes the domains of allosteric regulation by AMP/ADP/ATP. It is composed of two pairs of motifs called CBS because of their relationship to cystathione- $\beta$ -synthase sequences. Recent studies have clarified the mode of nucleotide binding to CBS in yeast and mammalian cells [8,9]. AMP and ATP play the role of allosteric activator and inhibitor respectively through binding to CBS1 and CBS3.

## Upstream Activators of AMPK

Current research suggests that there are at least three upstream AMPK kinases (AMPKKs) in mammals. The first one is LKB1 which includes STRAD  $\alpha$  (STE20-related adaptor protein  $\alpha$ ) and MO25 (scaffolding mouse 25 protein). It is the most widely expressed and indispensable for the gluconeogenic flux and glucose homeostasis [10,11]. Another AMPKK is Ca<sup>2+</sup>-calmodulin-protein kinase  $\beta$  (CaMKK  $\beta$ ) which can phosphorylate and activate AMPK in response to increased intracellular Ca<sup>2+</sup> concentrations, independent of any change in cellular AMP/ATP ratio [12]. The third AMPKK is transforming growth factor- $\beta$ -activated kinase1 (TAK-1) which regulates AMPK activity by phosphorylating Thr172. Genetic studies in yeast show that TAK1 may directly phosphorylate AMPK [13], but the intrinsic mechanism remains elusive.

## Downstream Targets of AMPK

AMPK regulates energy homeostasis both through direct phosphorylation of metabolic proteins and through signaling changes in gene expression. Some of the catabolic, energy-producing pathways AMPK upregulates include glucose uptake, glycolysis, fatty acid uptake, fatty acid oxidation, and autophagy [14]. AMPK also upregulates mitochondrial biogenesis; this aids the cell in energy production via some of the pathways just mentioned. Complementary to the upregulation of many catabolic pathways, AMPK also inhibits anabolic, energy-consuming pathways including gluconeogenesis, glycogen synthesis, fatty acid synthesis, triglyceride synthesis, isoprenoid synthesis, ribosomal RNA synthesis, and

DNA replication associated with the cell cycle [14]. In addition to its wide ranges of effects on energy homeostasis in the cell, AMPK also functions directly as an important energy sensor for cells. AMPK is activated in response to metabolic stress on the cell that lower the energy state of the cell by either inhibiting ATP production (i.e. ischemia, hypoxia, glucose deprivation) or accelerating ATP consumption (i.e. muscle contraction) [15]. Specifically, an increase in ADP: ATP and AMP: ATP ratios activate AMPK [16]. Increases in these ratios cause ADP and AMP to bind to the  $\gamma$  subunit of AMPK, displacing ATP. Conformational changes occur which both promote phosphorylation and inhibit dephosphorylation of AMPK [16]. AMP binding additionally causes an allosteric activation of AMPK [16]. Thr172 at the N-terminal of the  $\alpha$  subunit is the site at which AMPK is phosphorylated, activating AMPK [17].

## Drug Mechanisms of AMPK Activation

Many kinds of AMPK activators have been identified and studied. Drugs that target AMPK can activate AMPK either directly or indirectly. Direct activation of AMPK entails binding of the molecule to AMPK causing allosteric activation, promoting phosphorylation of Thr172, and/or inhibiting dephosphorylation of Thr 172. Indirect activation occurs from the molecule increasing the AMP: ATP and ADP: ATP ratios in the cell, often through inhibiting mitochondrial ATP production, and as a result, AMPK is activated by AMP and ADP as described earlier. Additionally, other activators have been identified to activate AMPK through unique pathways that are not as well characterized. Considering the extensive effects of AMPK within the cell it is no surprise that there are many and varied activators of AMPK. Many of these activators show promise for the treatment of a wide variety of health issues including diabetes, cancer, and cardiovascular disease. A selection of these activators are described in more detail below that show the highlight the diversity of activators in both origin, structure, and mechanism.

## Metformin

Metformin is the most commonly used drug for the treatment of type 2 diabetes [18]. In intact cells, metformin up-regulates AMPK activity, and thus increases fatty acid oxidation and down-regulates lipogenic genes, decreases hepatic glucose production and stimulates glucose uptake [19]. The related mechanism has been hypothesized that metformin activates AMPK by inhibiting complex I of the respiratory chain, resulting in a fall in cellular ATP concentration and an increase in the AMP: ATP ratio [20], therefore inhibiting dephosphorylation of AMPK and potentiating the phosphorylation of AMPK by the upstream kinase LKB1. Therefore, AMPK is deemed to be the core mediator of the glucose-lowering effect of metformin. AMPK may act as a potential therapeutic target in the prevention and treatment of type 2 diabetes and insulin resistance.

Recently metformin gained more popularity for the retrospective data suggesting that metformin was associated with a 30% lower cancer incidence [21]. Insulin resistance, obesity and type 2 diabetes are all related to an increased risk of cancer, resulting in higher mortality. Through activating AMPK, metformin can inhibit anabolic process including mTORC1 dependent protein biosynthesis, which in turn activates catabolic process and

reduces energy consuming process including cell proliferation [22]. Judging from research of p53 wild-type colorectal cancer cells, metformin-induced inactivation of mTOR by AMPK can also activate autophagy [23]. Study of endometrial, ovary, breast, pancreatic, lung, prostate and colon cancer, acute myeloid leukemia and glioma also showed the potential anti-tumorigenic effect of metformin [23–31]. There are also studies indicating that metformin can relieve heart ischemia and reperfusion injury, independent from its glucose-lowering effect, and its cardio-protective effect is mediated by activation of the Reperfusion Injury Salvage Kinase (RISK) pathway, activation of AMPK and by an increased formation of adenosine. In addition, metformin can modulate several cardiovascular risk factors and reduces the development of heart failure in murine models. Consequently, treatment with metformin might potentially improve cardiovascular outcome in patients at risk for myocardial ischemia, even if these patients do not have diabetes [32].

## Adiponectin

Adiponectin is a 30-KDa secretory protein secreted by adipocytes and was identified in the mid-1900s [33]. Circulating adiponectin has a wide range of multimers, including trimers, hexamers, and High Molecular Weight (HMW) multimers [34,35]. Adipo R1 and Adipo R2 serve as receptors of adiponectin. Studies of specific deletions in Adipo R1 or Adipo R2 demonstrate that Adipo R1 primarily mediates stimulation of AMPK phosphorylation, and Adipo R2 mediates PPAR alpha activity [36,37].

Adiponectin improves insulin sensitivity and reduces the adverse effects of inflammatory mediators in vascular cells, and the High Molecular Weight (HMW) multimers may contain the highest potency [38,39]. Adiponectin-KO mice have higher incidence to insulin resistance with high-fat feeding, and treatment with adiponectin can improve insulin sensitivity [40]. Direct correlation between adiponectin levels and proteinuria has been reported, however, there is conflicting data about adiponectin levels and mortality in patients with CKD or coronary artery disease [41–44]. Adiponectin protects against albuminuria through an Adipo R1 receptor pathway by stimulating AMPK and inhibiting ROS (Reactive Oxygen Species), but its relationship with Adipo R2 is still unknown [45]. Recent studies have suggested that adiponectin has an effect in maintaining normal podocyte structure, and relieving cardiovascular injury [46–50]. Adiponectin deficiency can exacerbate the transition from cardiac hypertrophy to heart failure during pressure overload because of disruption of AMPK-dependent angiogenic regulatory axis [51]. Adiponectin regulates the expression of the tumor suppressor gene LKB1 and that LKB1 is required for AMPK activation in human and mouse colon cancer cell lines [52].

## Activated Protein C

Activated Protein C (APC) is a vitamin-K dependent serine protease that down-regulates the blood clotting pathway by cleaving factors Va and VIIIa, which are required for thrombin and thrombomodulin in the blood clotting process [53,54]. In addition to its anticoagulant function, APC also reveals potent cytoprotective and anti-inflammatory action by decreasing expression of pro-inflammatory cytokines and inhibiting interaction and migration of leukocytes across the endothelium by inhibiting the NF- $\kappa$ B cascade [55,56]. APC is a safe

topical agent for healing chronic lower leg ulcers in patients with diabetes [57]. APC binds to Endothelial Protein C Receptor (EPCR), and subsequently activates Protease-Activator Receptor 1 (PAR-1) to exert a protective effect and an anti-apoptosis effect [58,59]. Some studies found that APC induced EPCR- and PAR1-dependent anti-apoptotic signaling pathways in certain tumor cells that enhanced survival and increased the potential of these cells to form metastatic foci [60–62]. Furthermore, APC decreases apoptosis via p53 inhibition, the transcription factor that regulates pro-apoptosis gene expression [63].

Our recent study suggests that APC relieves acute ischemic injury in the heart through activating the AMPK signaling pathway and inhibition of NF- $\kappa$ B and JNK cascades which is independent of its anticoagulant function. In addition to that, APC can specifically increase the oxidation of glucose over fatty acids as substrates in the ischemia/reperfusion heart [64,65]. Therefore, APC has the potential protective effects against ischemia/reperfusion injury in the heart, however, the molecular mechanism stimulated by APC remains to be further investigated.

## A-769662

A-769662 is a small organic molecule that is a member of the thienopyridine family of molecules. It was discovered as a direct activator of AMPK through screening of a chemical library of over 700,000 compounds [66]. A-769662 direct activation of AMPK is through binding which causes both inhibition of dephosphorylation of Thr172 and allosteric activation [67]. This is similar to the effect of AMP, however, the mechanism of AMPK activation by A-769662 is distinct from the mechanism of AMP and it is also specific to the  $\beta$ 1 isoform of AMPK [68,69]. A-769662 has been shown to protect the heart from ischemia-reperfusion injury and exert cytotoxicity in PANC-1 pancreatic cancer cells via activation of AMPK [67,70]. There is evidence that A-769662 is a direct inhibitor of certain ATPase's, including the Na<sup>+</sup>, K<sup>+</sup>-ATPase and some proteosomal ATPase's [71]. These findings present the idea that A-769662 may also contribute, in addition to direct AMPK activation, to indirect AMPK inactivation through inhibiting the Na<sup>+</sup>, K<sup>+</sup>-ATPase and subsequently decreasing the AMP: ATP and ADP: ATP ratios in the cell [71]. The validity of this hypothesis remains to be tested as well as whether A-769662 is a general ATPase inhibitor, however, it will be important to determine any off-target effects of A-769662 in the activation of AMPK.

## Salicylate

Salicylates are one of the oldest used drugs by humans. Salicylate, originally derived from willow bark, has been widely replaced by its acetylated form, aspirin, for its medicinal effects. Aspirin is quickly broken down to salicylate once it enters circulation [72]. Salicylates are able to improve insulin sensitivity in obese mice and in humans affected by type 2 diabetes and they have also been shown to reduce the risk of several cancers including colon, breast, and prostate cancers [73–75]. It has recently been shown that salicylate directly activates AMPK in a mechanism similar to A-769662 and that aspirin was also able to activate AMPK in colorectal cancer cells [76,77]. However, it remains to be fully

determined whether the improved diabetic and anticancer effects are directed through AMPK and also to what extent.

Aspirin is also used in treatment of cardiovascular disease in many cases, including during secondary prevention of vascular events in patients with history of cardiovascular disease, acute myocardial infarction, and, in some cases, primary prevention of vascular events [78]. The mechanism of this treatment is through the transfer of aspirin's acetyl group, which is known to irreversibly inhibit the COX1 and COX2 enzymes and subsequently inhibit blood clotting caused by platelets [79]. However, activation of AMPK is implicated in pre-conditioning of the heart, and the activation of AMPK by salicylate may provide another mechanism in which aspirin is able to treat cardiovascular disease [80]. It has yet to be determined whether salicylate activates AMPK in the heart as well as the doses of aspirin needed to activate AMPK in the heart and if this will be low enough to avoid the detrimental gastrointestinal effects of aspirin.

It is interesting to note that salsalate, an orally available form of salicylate which does not inhibit clotting or cause detrimental gastrointestinal effects, is able to improve glucose homeostasis in patients with insulin resistance or type 2 diabetes [81–83]. Salsalate or other non-acetylated forms of aspirin may show greater promise in certain treatments of type 2 diabetes, cancer, and cardiovascular disease for their ability to be given at higher doses than aspirin. Some off-target effects of salicylate include its ability to uncouple mitochondrial respiration, which contributes further to AMPK activation, and inhibition of prostanoid biosynthesis and the protein kinase IB kinase  $\beta$  in the NF- $\kappa$ B pathway [76,84]. These pathways may also play an important part in the therapeutic effects of salicylate, so further research is needed to determine the specific role activation of AMPK plays in treatment of the previously mentioned diseases.

## MIF20

Macrophage Migrating Inhibitory Factor (MIF) is a cytokine expressed in several tissues including vascular smooth muscle and cardiomyocytes, and it is involved in controlling inflammation [85–87]. It was shown to stimulate AMPK in the ischemic heart, and, therefore, provide a possible target for upregulation of AMPK in treatment of cardiovascular disease [88]. The increased susceptibility of myocardial ischemia of older patients with history of cardiovascular disease may be attributed to an impaired MIF-AMPK activation response so upregulation of AMPK through targeting of MIF could provide a new treatment for these patients [89]. Recently, structure-based molecular designs of MIF antagonists led to the identification of a few MIF agonists [90]. One of these agonists, MIF20, was then shown to protect the heart from ischemic injury [91]. Because of the tissue-specific expression of MIF, a MIF agonist such as MIF20 may provide a unique way to up-regulate AMPK in the treatment of cardiovascular disease. It is interesting to note that in Non-Small Cell Lung Carcinomas (NSCLCs) the MIF pathway through CD74 has been shown to inhibit AMPK activation in contrast with its activation of AMPK in nonmalignant cell types [92].

## 5-Aminoimidazole-4-Carboxamide Ribonucleoside (AICAR)

AICAR is an analogue of adenosine that is metabolized into 5-aminoimidazole-4-carboxamide ribonucleoside monophosphate (ZMP) within cells [93]. Because of its similar structure to AMP, ZMP is able to directly activate AMPK through the same mechanism as AMP. This involves ZMP binding to the  $\gamma$  subunit of AMPK and promoting phosphorylation, inhibiting dephosphorylation, and allosterically activating AMPK as mentioned earlier, however, ZMP is not as effective an activator as AMP is [16,93]. AICAR has been shown to improve glucose homeostasis and improve insulin sensitivity in diabetic animal models, and low doses of AICAR and ionizing radiation in the human prostate cancer cell line PC3 can inhibit cell proliferation, decrease viability, increase apoptosis, and generate reactive oxygen species in a dose- and time-dependent manner [94]. *In vitro*, aged myofibroblast maturation can be rescued through AICAR activation of AMPK and its downstream kinase p38MAPK (a non-canonical TGF- $\beta$  signaling pathway) [95]. However, AICAR has been mostly limited to use in studies to determine the downstream effects of AMPK activation because of limitations and adverse effects [96,97]. Some of the drawbacks of AICAR include that it is not orally available and must be intravenously injected [98]. Also, AICAR has variable potency, causes bradycardia, can lead to hypoglycemia, and it has deleterious effects on the blood lipid profile [96,98] (Table 1).

## Conclusions

AMPK plays a key role in the regulation of energy homeostasis within cells and at the whole-organism level both as a sensor and signaling molecule. Because of findings in the potential treatment of diseases such as type 2 diabetes, cancer, and cardiovascular disease with drugs that target and activate AMPK, it is important to identify and understand the mechanisms of the wide variety of drugs that activate AMPK. AMPK is widely expressed throughout the cell types of the body and is activated through both direct and indirect mechanisms, so it is also critical to take note of potential effects of these drugs beyond the cells of interest for treatment. It has already been shown that many of these drugs can have off-target effects.

Because there is tissue-specific expression of AMPK isoforms, another focus of research in the future may include tissue-specific targeting of AMPK activation. Direct activators of AMPK may provide the best possibility for this as they require specific binding to AMPK. It has already been shown that A-769662 and salicylate specifically target the  $\beta 1$  isoforms of AMPK, however, off-targets have already been identified for these drugs. Worth noting, a new small-molecule AMPK activator, ZLN024, has been shown to directly activate AMPK and have beneficial effects for db/db mice without affecting mitochondrial respiration or the ADP: ATP ratio of cells [99]. Findings such as this show the importance to keep identifying AMPK activators, as there may be more specific activators of AMPK with fewer off-targets possible that will lead to better treatment of diseases such as type 2 diabetes, cancer, and cardiovascular disease through AMPK activation.

## Acknowledgments

This study was supported by American Heart Association 14IRG18290014 and 12GRNT 11620029, American Diabetes Association Basic Sciences Grant 1-14-BS-131, National Natural Science Foundation of China (No. 31171121), the Major International (Regional) Joint Research Project 2008DFA31140 and 2010DFA32660, and Guangdong Natural Science Fund 10251008002000002 and S2011010005836.

## References

1. Beg ZH, Allmann DW, Gibson DM. Modulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity with cAMP and with protein fractions of rat liver cytosol. *Biochem Biophys Res Commun.* 1973; 54:1362–1369. [PubMed: 4356818]
2. Carlson CA, Kim KH. Regulation of hepatic acetyl coenzyme A carboxylase by phosphorylation and dephosphorylation. *J Biol Chem.* 1973; 248:378–380. [PubMed: 4692841]
3. Carling D, Clarke PR, Zammit VA, Hardie DG. Purification and characterization of the AMP-activated protein kinase. Co-purification of acetyl-CoA carboxylase kinase and 3-hydroxy-3-methylglutaryl-CoA reductase kinase activities. *Eur J Biochem.* 1989; 186:129–136. [PubMed: 2598924]
4. Young LH. A crystallized view of AMPK activation. *Cell Metab.* 2009; 10:5–6. [PubMed: 19583947]
5. Kazgan N, Williams T, Forsberg LJ, Brenman JE. Identification of a nuclear export signal in the catalytic subunit of AMP-activated protein kinase. *Mol Biol Cell.* 2010; 21:3433–3442. [PubMed: 20685962]
6. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. *Nat Rev Mol Cell Biol.* 2012; 13:251–262. [PubMed: 22436748]
7. Iseli TJ, Walter M, van Denderen BJ, Katsis F, Witters LA, et al. AMP-activated protein kinase beta subunit tethers alpha and gamma subunits via its C-terminal sequence (186–270). *J Biol Chem.* 2005; 280:13395–13400. [PubMed: 15695819]
8. Xiao B, Heath R, Saiu P, Leiper FC, Leone P, et al. Structural basis for AMP binding to mammalian AMP-activated protein kinase. *Nature.* 2007; 449:496–500. [PubMed: 17851531]
9. Townley R, Shapiro L. Crystal structures of the adenylate sensor from fission yeast AMP-activated protein kinase. *Science.* 2007; 315:1726–1729. [PubMed: 17289942]
10. Sakamoto K, Zarrinpashneh E, Budas GR, Pouleur AC, Dutta A, et al. Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKalpha2 but not AMPKalpha1. *Am J Physiol Endocrinol Metab.* 2006; 290:E780–E788. [PubMed: 16332922]
11. Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. *J Biol.* 2003; 2:28. [PubMed: 14511394]
12. Woods A, Dickerson K, Heath R, Hong SP, Momcilovic M, et al. Ca<sup>2+</sup>/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. *Cell Metab.* 2005; 2:21–33. [PubMed: 16054096]
13. Momcilovic M, Hong SP, Carlson M. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. *J Biol Chem.* 2006; 281:25336–25343. [PubMed: 16835226]
14. Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. *Genes Dev.* 2011; 25:1895–1908. [PubMed: 21937710]
15. Hardie DG, Scott JW, Pan DA, Hudson ER. Management of cellular energy by the AMP-activated protein kinase system. *FEBS Lett.* 2003; 546:113–120. [PubMed: 12829246]
16. Hardie DG, Ross FA, Hawley SA. AMP-activated protein kinase: a target for drugs both ancient and modern. *Chem Biol.* 2012; 19:1222–1236. [PubMed: 23102217]
17. Hawley SA, Davison M, Woods A, Davies SP, Beri RK, et al. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. *J Biol Chem.* 1996; 271:27879–27887. [PubMed: 8910387]



18. Zhang BB, Zhou G, Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. *Cell Metab.* 2009; 9:407–416. [PubMed: 19416711]
19. Zhou G, Myers R, Li Y, Chen Y, Shen X, et al. Role of AMP-activated protein kinase in mechanism of metformin action. *J Clin Invest.* 2001; 108:1167–1174. [PubMed: 11602624]
20. El-Mir MY, Nogueira V, Fontaine E, Avéret N, Rigoulet M, et al. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. *J Biol Chem.* 2000; 275:223–228. [PubMed: 10617608]
21. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. *BMJ.* 2005; 330:1304–1305. [PubMed: 15849206]
22. Vazquez-Martin A, Oliveras-Ferreros C, Cufí S, Martin-Castillo B, Menendez JA. Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells. *Curr Mol Med.* 2010; 10:674–691. [PubMed: 20712585]
23. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. *Cancer Res.* 2007; 67:6745–6752. [PubMed: 17638885]
24. Kisfalvi K, Eibl G, Sinnott-Smith J, Rozenfurt E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. *Cancer Res.* 2009; 69:6539–6545. [PubMed: 19679549]
25. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. *Oncogene.* 2008; 27:3576–3586. [PubMed: 18212742]
26. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, et al. Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy. *Gynecol Oncol.* 2010; 116:92–98. [PubMed: 19822355]
27. Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, et al. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. *Gynecol Oncol.* 2008; 110:246–250. [PubMed: 18495226]
28. Green AS, Chapuis N, Maciel TT, Willems L, Lambert M, et al. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. *Blood.* 2010; 116:4262–4273. [PubMed: 20668229]
29. Isakovic A, Harhaji L, Stevanovic D, Markovic Z, Sumarac-Dumanovic M, et al. Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. *Cell Mol Life Sci.* 2007; 64:1290–1302. [PubMed: 17447005]
30. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, et al. Metformin prevents tobacco carcinogen--induced lung tumorigenesis. *Cancer Prev Res (Phila).* 2010; 3:1066–1076. [PubMed: 20810672]
31. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. *Cancer Res.* 2006; 66:10269–10273. [PubMed: 17062558]
32. El Messaoudi S, Rongen GA, Riksen NP. Metformin therapy in diabetes: the role of cardioprotection. *Curr Atheroscler Rep.* 2013; 15:314. [PubMed: 23423523]
33. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. *J Biol Chem.* 1996; 271:10697–10703. [PubMed: 8631877]
34. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. *J Biol Chem.* 2003; 278:40352–40363. [PubMed: 12878598]
35. Onay-Besikci A, Altarejos JY, Lopaschuk GD. gAd-globular head domain of adiponectin increases fatty acid oxidation in newborn rabbit hearts. *J Biol Chem.* 2004; 279:44320–44326. [PubMed: 15269215]
36. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. *Nat Med.* 2002; 8:1288–1295. [PubMed: 12368907]

37. Fasshauer M, Klein J, Kralisch S, Klier M, Lossner U, et al. Growth hormone is a positive regulator of adiponectin receptor 2 in 3T3-L1 adipocytes. *FEBS Lett.* 2004; 558:27–32. [PubMed: 14759511]
38. Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. *Diabetes.* 2006; 55:1537–1545. [PubMed: 16731815]
39. Goldstein BJ, Scalia R. Adiponectin: A novel adipokine linking adipocytes and vascular function. *J Clin Endocrinol Metab.* 2004; 89:2563–2568. [PubMed: 15181024]
40. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. *Nat Med.* 2002; 8:731–737. [PubMed: 12068289]
41. Laughlin GA, Barrett-Connor E, May S, Langenberg C. Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. *Am J Epidemiol.* 2007; 165:164–174. [PubMed: 17101706]
42. Looker HC, Krakoff J, Funahashi T, Matsuzawa Y, Tanaka S, et al. Adiponectin concentrations are influenced by renal function and diabetes duration in Pima Indians with type 2 diabetes. *J Clin Endocrinol Metab.* 2004; 89:4010–4017. [PubMed: 15292342]
43. Menon V, Li L, Wang X, Greene T, Balakrishnan V, et al. Adiponectin and mortality in patients with chronic kidney disease. *J Am Soc Nephrol.* 2006; 17:2599–2606. [PubMed: 16885405]
44. Jorsal A, Tarnow L, Frystyk J, Lajer M, Flyvbjerg A, et al. Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. *Kidney Int.* 2008; 74:649–654. [PubMed: 18496510]
45. Ix JH, Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. *J Am Soc Nephrol.* 2010; 21:406–412. [PubMed: 20150538]
46. Sharma K. The link between obesity and albuminuria: adiponectin and podocyte dysfunction. *Kidney Int.* 2009; 76:145–148. [PubMed: 19404275]
47. Sharma K, Ramachandrarao S, Qiu G, Usui HK, Zhu Y, et al. Adiponectin regulates albuminuria and podocyte function in mice. *J Clin Invest.* 2008; 118:1645–1656. [PubMed: 18431508]
48. Zoccali C, Mallamaci F. Obesity, diabetes, adiponectin and the kidney: a podocyte affair. *Nephrol Dial Transplant.* 2008; 23:3767–3770. [PubMed: 18802210]
49. Goldstein BJ, Scalia RG, Ma XL. Protective vascular and myocardial effects of adiponectin. *Nat Clin Pract Cardiovasc Med.* 2009; 6:27–35. [PubMed: 19029992]
50. Shibata R, Ouchi N, Murohara T. Adiponectin and cardiovascular disease. *Circ J.* 2009; 73:608–614. [PubMed: 19261992]
51. Shimano M, Ouchi N, Shibata R, Ohashi K, Pimentel DR. Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response. *J Mol Cell Cardiol.* 2010; 49:210–220. [PubMed: 20206634]
52. Moon HS, Mantzoros CS. Adiponectin and metformin additively attenuate IL1 $\beta$ -induced malignant potential of colon cancer. *Endocr Relat Cancer.* 2013; 20:849–859. [PubMed: 24157941]
53. Esmon CT. Molecular events that control the protein C anticoagulant pathway. *Thromb Haemost.* 1993; 70:29–35. [PubMed: 8236111]
54. Walker FJ, Fay PJ. Regulation of blood coagulation by the protein C system. *FASEB J.* 1992; 6:2561–2567. [PubMed: 1317308]
55. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. *Blood.* 2007; 109:3161–3172. [PubMed: 17110453]
56. Elphick GF, Sarangi PP, Hyun YM, Hollenbaugh JA, Ayala A, et al. Recombinant human activated protein C inhibits integrin-mediated neutrophil migration. *Blood.* 2009; 113:4078–4085. [PubMed: 19244161]
57. Whitmont K, McKelvey KJ, Fulcher G, Reid I, March L, et al. Treatment of chronic diabetic lower leg ulcers with activated protein C: a randomised placebo-controlled, double-blind pilot clinical trial. *Int Wound J.* 2013
58. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. *Science.* 2002; 296:1880–1882. [PubMed: 12052963]

59. Joyce DE, Grinnell BW. Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB. *Crit Care Med.* 2002; 30:S288–S293. [PubMed: 12004250]
60. Beaulieu LM, Church FC. Activated protein C promotes breast cancer cell migration through interactions with EPCR and PAR-1. *Exp Cell Res.* 2007; 313:677–687. [PubMed: 17254565]
61. Suzuki K, Hayashi T. Protein C and its inhibitor in malignancy. *Semin Thromb Hemost.* 2007; 33:667–672. [PubMed: 18000793]
62. Antón I, Molina E, Luis-Ravelo D, Zanduetta C, Valencia K, et al. Receptor of activated protein C promotes metastasis and correlates with clinical outcome in lung adenocarcinoma. *Am J Respir Crit Care Med.* 2012; 186:96–105. [PubMed: 22461368]
63. Cheng T, Liu D, Griffin JH, Fernández JA, Castellino F, et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. *Nat Med.* 2003; 9:338–342. [PubMed: 12563316]
64. Wang J, Yang L, Rezaie AR, Li J. Activated protein C protects against myocardial ischemic/reperfusion injury through AMP-activated protein kinase signaling. *J Thromb Haemost.* 2011; 9:1308–1317. [PubMed: 21535395]
65. Costa R, Morrison A, Wang J, Manithody C, Li J, et al. Activated protein C modulates cardiac metabolism and augments autophagy in the ischemic heart. *J Thromb Haemost.* 2012; 10:1736–1744. [PubMed: 22738025]
66. Cool B, Zinker B, Chiou W, Kifle L, Cao N, et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. *Cell Metab.* 2006; 3:403–416. [PubMed: 16753576]
67. Kim AS, Miller EJ, Wright TM, Li J, Qi D, et al. A small molecule AMPK activator protects the heart against ischemia-reperfusion injury. *J Mol Cell Cardiol.* 2011; 51:24–32. [PubMed: 21402077]
68. Sanders MJ, Ali ZS, Hegarty BD, Heath R, Snowden MA, et al. Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. *J Biol Chem.* 2007; 282:32539–32548. [PubMed: 17728241]
69. Treebak JT, Birk JB, Hansen BF, Olsen GS, Wojtaszewski JF. A-769662 activates AMPK beta1-containing complexes but induces glucose uptake through a PI3-kinase-dependent pathway in mouse skeletal muscle. *Am J Physiol Cell Physiol.* 2009; 297:C1041–C1052. [PubMed: 19657063]
70. Wang B, Wang XB, Chen LY, Huang L, Dong RZ. Belinostat-induced apoptosis and growth inhibition in pancreatic cancer cells involve activation of TAK1-AMPK signaling axis. *Biochem Biophys Res Commun.* 2013; 437:1–6. [PubMed: 23743198]
71. Benziane B, Björnholm M, Lantier L, Viollet B, Zierath JR, et al. AMP-activated protein kinase activator A-769662 is an inhibitor of the Na(+)-K(+)-ATPase. *Am J Physiol Cell Physiol.* 2009; 297:C1554–C1566. [PubMed: 19828836]
72. Higgs GA, Salmon JA, Henderson B, Vane JR. Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity. *Proc Natl Acad Sci U S A.* 1987; 84:1417–1420. [PubMed: 3103135]
73. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. *Science.* 2001; 293:1673–1677. [PubMed: 11533494]
74. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. *J Clin Invest.* 2002; 109:1321–1326. [PubMed: 12021247]
75. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. *Lancet Oncol.* 2009; 10:501–507. [PubMed: 19410194]
76. Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevzoff C, et al. The ancient drug salicylate directly activates AMP-activated protein kinase. *Science.* 2012; 336:918–922. [PubMed: 22517326]

77. Din FV, Valanciute A, Houde VP, Zibrova D, Green KA, et al. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. *Gastroenterology*. 2012; 142:1504–1515. [PubMed: 22406476]
78. Hennekens CH, Dalen JE. Aspirin in the treatment and prevention of cardiovascular disease: past and current perspectives and future directions. *Am J Med*. 2013; 126:373–378. [PubMed: 23499330]
79. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. *Annu Rev Pharmacol Toxicol*. 1998; 38:97–120. [PubMed: 9597150]
80. Sukhodub A, Jovanovi S, Du Q, Budas G, Clelland AK, et al. AMP-activated protein kinase mediates preconditioning in cardiomyocytes by regulating activity and trafficking of sarcolemmal ATP-sensitive K(+) channels. *J Cell Physiol*. 2007; 210:224–236. [PubMed: 17044064]
81. Goldfine AB, Conlin PR, Halperin F, Koska J, Permana P, et al. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. *Diabetologia*. 2013; 56:714–723. [PubMed: 23370525]
82. Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. *Diabetes Care*. 2008; 31:289–294. [PubMed: 17959861]
83. Steinberg GR, Dandapani M, Hardie DG. AMPK: mediating the metabolic effects of salicylate-based drugs? *Trends Endocrinol Metab*. 2013; 24:481–487. [PubMed: 23871515]
84. Brody TM. Action of sodium salicylate and related compounds on tissue metabolism in vitro. *J Pharmacol Exp Ther*. 1956; 117:39–51. [PubMed: 13320299]
85. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, et al. MIF as a glucocorticoid-induced modulator of cytokine production. *Nature*. 1995; 377:68–71. [PubMed: 7659164]
86. Burger-Kentischer A, Goebel H, Seiler R, Fraedrich G, Schaefer HE, et al. Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. *Circulation*. 2002; 105:1561–1566. [PubMed: 11927523]
87. Willis MS, Carlson DL, Dimaio JM, White MD, White DJ, et al. Macrophage migration inhibitory factor mediates late cardiac dysfunction after burn injury. *Am J Physiol Heart Circ Physiol*. 2005; 288:H795–H804. [PubMed: 15388499]
88. Miller EJ, Li J, Leng L, McDonald C, Atsumi T, et al. Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. *Nature*. 2008; 451:578–582. [PubMed: 18235500]
89. Ma H, Wang J, Thomas DP, Tong C, Leng L, et al. Impaired macrophage migration inhibitory factor-AMP-activated protein kinase activation and ischemic recovery in the senescent heart. *Circulation*. 2010; 122:282–292. [PubMed: 20606117]
90. Jorgensen WL, Gandavadi S, Du X, Hare AA, Trofimov A, et al. Receptor agonists of macrophage migration inhibitory factor. *Bioorg Med Chem Lett*. 2010; 20:7033–7036. [PubMed: 20971005]
91. Wang J, Tong C, Yan X, Yeung E, Gandavadi S, et al. Limiting cardiac ischemic injury by pharmacological augmentation of macrophage migration inhibitory factor-AMP-activated protein kinase signal transduction. *Circulation*. 2013; 128:225–236. [PubMed: 23753877]
92. Brock SE, Rendon BE, Yaddanapudi K, Mitchell RA. Negative regulation of AMP-activated protein kinase (AMPK) activity by macrophage migration inhibitory factor (MIF) family members in non-small cell lung carcinomas. *J Biol Chem*. 2012; 287:37917–37925. [PubMed: 22988252]
93. Corton JM, Gillespie JG, Hawley SA, Hardie DG. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? *Eur J Biochem*. 1995; 229:558–565. [PubMed: 7744080]
94. Isebaert SF, Swinnen JV, McBride WH, Begg AC, Haustermans KM. 5-aminoimidazole-4-carboxamide riboside enhances effect of ionizing radiation in PC3 prostate cancer cells. *Int J Radiat Oncol Biol Phys*. 2011; 81:1515–1523. [PubMed: 21944462]
95. Cieslik KA, Trial J, Entman ML. Defective myofibroblast formation from mesenchymal stem cells in the aging murine heart rescue by activation of the AMPK pathway. *Am J Pathol*. 2011; 179:1792–1806. [PubMed: 21819956]

96. Song XM, Fiedler M, Galuska D, Ryder JW, Fernström M, et al. 5-Aminoimidazole-4-carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice. *Diabetologia*. 2002; 45:56–65. [PubMed: 11845224]
97. Iglesias MA, Ye JM, Frangioudakis G, Saha AK, Tomas E, et al. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. *Diabetes*. 2002; 51:2886–2894. [PubMed: 12351423]
98. Moussa A, Li J. AMPK in myocardial infarction and diabetes: the yin/yang effect. *Acta Pharmaceutica Sinica B*. 2012; 2:368–378.
99. Zhang LN, Xu L, Zhou HY, Wu LY, Li YY, et al. Novel small-molecule AMP-activated protein kinase allosteric activator with beneficial effects in db/db mice. *PLoS One*. 2013; 8:e72092. [PubMed: 23977216]

**Table 1**

AMPK activators and research stages in disease treatment.

Type of molecule	Diabetes	Cancer	Cardiovascular Disease
<b>Metformin</b>	Clinical Use [18]	Clinical Research [21] Cell Research [23]	Animal Research [32]
<b>Adiponectin</b>	Animal Research [40]	Cell Research [52]	Animal Research [51]
<b>APC</b>	Clinical Research [57]	Clinical Research [60–62] Cell Research [58,59]	Animal Research [63]
<b>A-769662</b>	Animal Research [66]	Cell Research [67,70]	Animal Research [67]
<b>Salicylate</b>	Clinical Research [81–83]	Cell Research [76,77]	Clinical Use [78]
<b>MIF20</b>	NA	Cell Research [92]	Animal Research [88]
<b>AICAR</b>	Animal Research [96,97]	Clinical Research [94]	Animal Research [95]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript